*No estudo que avaliou o impacto da M184V/I após switch para BIC/FTC/TAF, os dados de supressão virológica (RNA do HIV-1 < 50cp/mL) na semana 48 foram: 98% (285/290) de todos os indivíduos; 95% (40/42) daqueles que apresentavam M184V/I e 99% (232/235) daqueles que não apresentavam a M184V/I.
1. ANDREATTA, K. et al. High prevalence of previously undocumented baseline M184V/I does not affect virologic outcome in virologically suppressed patients switching to bictegravir/emtricitabine/tenofovir alafenamide from a boosted protease inhibitor based regimen. P298. Journal of the International AIDS Society; 21(S8):e25187, 2018.
2. DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Disponível em: <https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>. Acesso em: 06 nov. 2018.
3. WAINBERG, M. Primary HIV Resistance, Antiretroviral Therapy Regimens, and the M184V Mutation: Highlights of the XIII Drug Resistance Workshop: A Canadian Perspective. In: MEDSCAPE. Disponível em: <https://www.medscape.org/viewarticle/484066>. Acesso em: 06 nov. 2018.
4. OLEARO, F. et al. The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir regimens prescribed in treatment-experienced patients. O214. Journal of the International AIDS Society; 21(S8):e25187, 2018.
5. OLEARO, F. et al. The impact of M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir regimens prescribed in treatment-experienced patients. In: Glasgow HIV Drug Therapy, 2018. Disponível em: <http://www.natap.org/2018/GLASGOW/GLASGOW_30.htm>. Acesso em: 07 nov. 2018.
6. SPAGNUOLO, V. et al. Bictegravir. Curr Opin HIV AIDS; 13(4):326-333, 2018.